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Molecular self-assembly has enabled the fabrication of biologically inspired, advanced nanostructures as lipid-based nanovesicles (L-NVs). The oldest L-NVs, 
liposomes have been widely proposed as potential candidates for drug delivery, diagnostic and/or theragnostic applications and some liposome-based drug 
products have already stepped from the lab-bench to the market. This success is attributed to their ability to encapsulate both hydrophobic and/or 
hydrophilic molecules, efficiently carry and protect them within the body and finally deliver them at the target site. These positive features are also coupled 
with high biocompatibility. However, liposomes still present some un-solved drawbacks, as poor colloidal stability, short shelf-life, restricted and expensive 
conditions of preparation because of the inherent nature of their fundamental constituents (phospholipids). The new tools available in controlled molecules 
self-assembly have significantly advanced the field of L-NVs design and synthesis, and non-liposomal L-NVs have been recently developed; this new 
generation of nanovesicles can represent a paradigm shift in Nanomedicine: they may complement liposomes, showing their advantages and overcoming 
most of their drawbacks. Clearly, being still young, their rocky way to the clinic first, and then to the market has just started and it is still long, but they have 
all the potentialities to reach their objective target. The purpose of this review is to first present the large plethora of L-NVs available, focusing on this new 
generation of non-liposomal L-NVs and showing their similarities and differences with respect to their ancestors (liposomes). Since the overspread of a 
nanomaterial to the market is also strongly dependent on the availability of technological-scale preparation methods, we will also extensively review the 
current approaches exploited for L-NVs production. The most cutting-edge approaches based on compressed-fluid (CF) technologies will be here highlighted 
since they show the potential to represent a game-changing in the production of L-NVs, favouring their step from the bench to the market. Finally, we will 
briefly discuss L-NVs applications in Nanomedicine, looking also to their future perspectives. 
Introduction 
Nanotechnology is a buzzword of this millennium which has transformed the face of research in science and technology. 
Nanoparticles have been extensively proposed as alternative to conventional approaches in many technologically-advanced 
fields like the electronic, petrochemical, food and pharmaceutical/biomedical industry 1–4. The application of nanotechnology to 
the biomedical field gave origin to the concept of Nanomedicine, becoming a highly studied field 5–10. According to the European 
Science Foundation, Nanomedicine is the science and technology of diagnosing, treating and preventing disease and traumatic 
injury, of relieving pain, and of preserving and improving human health, using molecular tools and molecular knowledge of the 
human body 11. In the pharmaceutical industry, nanomaterials and especially nanoparticles have found their application in (i) the 
rescue of some drugs, presenting promising therapeutic value, but not exploited because of the difficulties inherent to their 
formulation/compounding; (ii) the “make-over” of drugs already used in clinical practice 12,13; (iii) administration of 
biopharmaceuticals (therapeutic proteins, DNA, RNAs, antisense ODNs, cells), which are an emerging generation of delicate and 
challenging therapeutics 14,15. In general, nanoparticles based formulations can overcome the drawbacks of the conventional 
ones; they allow the administration of drugs in a more effective and safe manner by increasing their solubility and stability, 
targeting specific organs and tissues, reducing their rapid clearance from the body and their side effects. Among all the proposed 
nanoparticles, such as inorganic nanoparticles, polymeric nanoparticles, carbon nanotubes and nanogels 16–21, lipid-based 
nanovesicles (L-NVs) have been intensively investigated, because from the very beginning they have shown excellent 
performances. 
 
 
 
 
 
 
 
 
Figure 1. Schematic representation of lipid-based vesicles. a) classification of vesicles regarding their size and lamellarity; b) 
structure of the vesicles bilayer (left side) and examples of (bio)-actives to be physically encapsulated or chemically conjugated.  
 
L-NVs are regarded as small sphere-shaped bilayered vesicles containing lipids in its constitution. Usually, vesicles are broadly 
classified into small unilamellar vesicles/nanovesicles (SUVs, size < 200 nm and single bilayer), large unilamellar vesicles (LUVs, 
size ranging from 200 - 1000 nm and single bilayer), giant unilamellar vesicles (GUVs, size > 1000 nm and single bilayer), 
multilamellar vesicles (MLVs, consisting of several concentric bilayers) and multivesicular vesicles (MVVs, composed by several 
small vesicles entrapped into larger ones) (Figure 1a). The surface of the vesicles can be easily functionalized with different 
ligands (Figure 1b), allowing the production of smart, multifunctional systems. In general, many parameters need to be 
controlled when nanocarriers are synthesized and among them the size, the morphology and the surface properties are the most 
relevant since they govern the interactions among nanocarriers and cells. Furthermore, the membrane organization also needs 
to be taken into account in the case of L-NVs. Smaller size (100-200 nm), are usually requested as well as high homogeneity in 
size and structure. For this reason, SUVs have attracted great attention in the drug delivery field since they have the right 
compromise of size: they are big enough to avoid the rapid clearance through the kidneys and small enough to present a minimal 
uptake by the mononuclear phagocytic system, facilitating their longer circulation lifetime in the body and hence a higher 
possibility to reach the target cells 22. Moreover, SUVs can easily accumulate within tumors through the so-called enhanced 
permeability and retention (EPR) effect and thereby be applied in cancer therapy 23,24. On the other hand SUVs, compared to 
MLVs or MVVs, allow a more accessible and homogeneous membranes functionalization and this finally turns in a homogeneous 
and sharp response of the system to an external stimulus, i.e. allowing the homogeneous release of the drug at the target site, if 
the vesicles are functionalized with a drug. Among lipid-based SUVs, liposomes have been the first ones developed and they 
have quickly stepped from the lab-bench to the clinic and finally they have imposed their presence on the market. Indeed, some 
liposomal-based therapeutic systems have been already approved by regulatory agencies and others are nowadays under clinical 
evaluations 15,25,26. Liposomes were discovered by Bangham and co-worker 50 years ago, and are constituted by an aqueous core 
enclosed by single or multiple concentric phospholipid bilayers (Figure 2a). The first formulation of liposomes was composed by 
natural phospholipids 27. Nowadays, liposomes are composed by naturally and/or synthetic phospholipids, such as 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), and phosphatidylglycerol (PG) 28–30. 
Liposomes have several advantages as drug delivery systems (DDS) due to their high biocompatibility 31, and their ability to 
entrap both hydrophilic and hydrophobic drugs into their aqueous core or in their lipid bilayers, respectively 32. However, they 
show some drawbacks as poor colloidal and chemical stabilities, rapidly clearance from the blood after intravenous 
administration 33, high permeability of their membranes causing leaks of the entrapped drugs due to the intrinsic rotational 
freedom of the phospholipids, etc. In order to overcome these problems, new liposomal-based nanovesicles have been 
developed. For example, surface-modified liposomes by the means of glycolipids, mimicking the erythrocyte membrane, or with 
hydrophilic synthetic polymers, such as poly(ethylene glycol) (PEG) 34 (stealth liposomes), have been synthesized and they have 
shown a longer circulation time. Or in order to improve the physical stability of liposomes, cholesterol (Chol) has been added as 
additional component of the lipid bilayers, since it can enhance membrane rigidity and in vitro and in vivo stability 35,36. As 
regards their poor colloidal stability and short shelf-life, many attempts have been done, but without success37. In fact, liposomes 
correspond to a metastable state, which is achieved by the input of external energy (e.g., sonication or mechanical filtration). The 
stability of these structures is kinetically limited because the phospholipids are highly insoluble, thus they have the tendency to 
aggregate (equilibrium state) 38,39. Usually liposomes are stored as dry products which can be reconstituted prior to administration 
40. All the mentioned restricted conditions of preparation and storage, besides the elevated price of phospholipids have 
addressed the research towards new vesicular formulations, made of cheaper and more stable membrane components 41–45. 
New findings in molecular self-assembly made possible to design and synthesize new biologically inspired, advanced, almost 
“tailor-made” (i.e. nanovesicles suited for a particular purpose) L-NVs. For instance, it has been discovered that certain lipids can 
self-assemble in appropriate conditions with surfactants 43,46–48, polymers 49–51, polypeptides 52–54, and furellene-based 
derivatives 55–57, leading to a new generation of non-liposomal vesicle-like structures containing at least one natural or synthetic 
lipid in their composition 58. The driving force for the self-assembly through weak, noncovalent interactions of such molecules in 
water is the inherent hydrophobic character of the lipids. Depending on their composition, nanovesicles showing various 
physicochemical properties (size, charge density, functionality, morphology and lamellarity) and drug encapsulation efficiencies 
can be produced 59–61. Moreover, multitasking nanocarriers can be generated with specific dual or multiple mode functions, such 
as active targeting by incorporating targeting ligands, prolonged circulation in the blood, and triggered release of the drug under 
local stimuli (like pH, temperature, enzymatic changes) 62–64. Many papers and reviews have been published, describing the 
oldest representatives of L-NVs, i.e. liposomes 20,28,31,58,65–68. Conversely, the purpose of this review is to provide a description of 
the new generation of non-liposomal L-NVs, since they are still not well-known. They have already demonstrate huge potential, 
especially at pre-clinical stage 69–74 but in order to be overspread to the market, they need to be translated in pharmaceutical 
products, both showing excellent performances in vivo and providing manufacturing processes viable at industrial scale for their 
production. Because of that, we will also review the current synthetic methods for L-NVs production, highlighting the 
technologies that can support non-liposomal L-NVs in their rocky way to the market. Among these, we will extensively describe 
compressed fluids (CF)-based technologies since we believe they can represent a game-changing in L-NVs production. In fact, CF-
based technologies have already shown their potential in terms of granting high throughput of homogeneous, high quality L-NVs 
and high compliance with the constraints imposed by Good Manufacturing Practices (GMP). Furthermore, it has been assessed 
that they are easily scalable at industrial level and they have been recognized as green technologies, making them even more 
appealing for the pharmaceutical industry. The last part of the review will be dedicated to the currently biomedical applications 
of L-NVs in Nanomedicine, finally looking to their future perspectives. It is worth to point out here that even though liposomes 
are not meant to be the main characters of this review, because they are the “oldest” and “more developed” L-NVs, they will be 
often re-called in this review and used either as “model” or “antimodel” in the comparison with non-liposomal L-NVs. 
Non-Liposomal Lipid-Based Nanovesicles: Classification 
In order to describe the most important types of non-liposomal L-NVs, we have divided them in different groups depending on 
their membrane components, where at least one of them is a natural and/or a synthetic lipid. The most important properties of 
each system here described are reported in Table 1. 
 
Niosomes 
Niosomes (Figure 2c), or non-ionic surfactant vesicles, have gained increasing scientific attention as drug delivery systems with 
respect to conventional liposomes (Figure 2a), due to the use of surfactants in their formulation, which are cheaper and more 
stable alternatives than phospholipids. Niosomes are prepared by mixting  nonionic surfactants, such as alkyl ether, alkyl esters 
or alkyl amides, fatty acids and amino acid compounds, with or without Chol or other lipids and then, subsequently hydrating the 
mixture 43,46,75. The formation of such vesicle-like structures depends on the hydrophilic–lipophilic balance (HLB) of the 
surfactant, the chemical structure of the components and their geometry and aspect ratio 46,76. Addition of Chol to these 
structures improves the rigidity of the bilayer, reducing the permeability of vesicles to encapsulated drugs,  preventing thereby 
the leakages, and enhancing the drug encapsulation 59,60,64. The size range of niosomes includes nano and submicron sizes, and 
the vesicle structures can be unilamellar or multilamellar 77. Owing to vesicle structure, niosomes are able to entrap both 
hydrophilic and hydrophobic drugs, as liposomes do. Interestingly, surfactants can be easily chemically modified allowing a high 
versatility of vesicular structures. Niosomes are quite stable at least for few months depending on their membrane components 
and additive agents 78,79. Moreover, the high chemical stability of surfactants, compared with phospholipids, makes niosomes 
purification, handling and storage much more easier 80–83. Niosomes formulations have been shown good in vitro and in vivo 
results for the delivery of both pharmaceuticals and biopharmaceuticals 43,84,85. For example, promising transfection efficiencies 
has been achieved with niosomes loaded with plasmid DNA after subretinal, intravitreal and brain injections in rats 70. In another 
study, insulin permeability has been evaluated by Caco-2 cell monolayer, and it has been observed an enhancement of insulin 
permeation  up to 4-fold by niosomal formulation compare to insulin alone 79. Also, niosomes loaded with glucocorticoids, such 
as beclomethasone dipropionate (BDP), show promising results in vitro for the treatment of inflammatory lung diseases. Human 
lung fibroblast cells showed an increase of the drug anti-inflammatory activity after treatment with niosomal formulation 85. 
Despite the promising results achieved both in vitro and in vivo, niosomes have some disadvantages related to their poor 
physical stability and sterilization issues 86,87.  
 
Table 1: Examples of non-liposomal L-NVs and their main characteristics. 
System Composition 
Size 
Lamellarity 
Stability 
Example of 
preclinical study 
(refs) 
Niosomes Chol/Non Ionic Surfactants 
Nano and sub-micron range 
Unilamellar & multilamellar 
Short-term stability 
 (few months) 
In vitro 70,79,88,85 
In vivo 70  
Transfersomes Phospholipids/Surfactants 
Nano and sub-micron range 
Unilamellar &multilamellar 
Short-term stability  
(few months) 
In vitro 42,89–91 
In vivo 42,71,89 
Ethosomes Phospholipids/Alcohols 
Nano and sub-micron range 
Unilamellar &multilamellar 
Short-term stability  
(few months) 
In vitro 69,92–94 
In vivo 69 
Sphingosomes Sphingolipids/Chol 
Nano and sub-micron range 
Unilamellar & multilamellar 
Long-term stability 
(several months) 
In vitro 95 
In vivo 95,96 
Ufasomes Fatty Acid/Surfactants 
Nano and sub-micron range 
Unilamellar & multilamellar 
Short-term stability  
(few months) 
In vitro 97–99 
In vivo 99 
Pharmacosomes Drug/ Phospholipids 
Nano and micron range 
Unilamellar & multilamellar 
Short-term stability  
(few months) 
In vitro 100,101 
In vivo 101 
Virosomes 
Phospholipid/ Viral envelope 
proteins 
Nano and sub-micron range 
Unilamellar & multilamellar 
Short-term stability  
(few months) 
In vitro 73,102–104 
In vivo 73,102–105 
Quatsomes Chol/Cationic Surfactants 
Nano range 
Unilamellar 
Long-term stability  
(several years) 
In vitro 74 
 
Transfersomes 
Liposomes as well as niosomal systems have showed low skin penetration due to the breaking of vesicles, leakage of the 
encapsulated drug, aggregation and fusion of the vesicles. To overcome such drawbacks new vesicular systems, called 
transfersomes, have been recently developed. Transfersomes were introduced in the early 1990s as a highly deformable – elastic 
or ultraflexible – vesicular systems, which are able to penetrate the mammalian skin intact when applied under non-occlusive 
conditions 106. Transfersomes are composed mainly by phospholipids (such as soya PC, egg PC, dipalmityl PC, among others) and 
surfactants (such as span 80, tween 80, sodium cholate, among others) as edge activators (Figure 2b) 47,48. Usually these edge 
activators are single chain surfactants that have the role to produce higher radius of curvature, destabilizing the lipid bilayer of 
vesicles, and thus increasing its deformability. Transfersomes size are in the nano and sub-micron range, and regarding 
lamellarity vesicles are unilamellar 90,107. These new kind of vesicles, 
are good candidates for transdermal delivery of both low and high 
molecular weight drugs, due to their high deformability allowing 
them to penetrate the skin by squeezing themselves along the 
intracellular sealing lipid of the stratum corneum 91,108–111. For 
example, transfersomal gel loaded with 5-fluorouracil, an 
antineoplastic drug, showed promising results in vivo for the 
treatment of skin cancer. The gel containing the transfersomal 
formulation showed better skin deposition and skin penetration than 
the drug commercially available, without any irritation of the skin 
after treatment 112. However, transfersomes formulations have some 
limitations, like their poor chemical stability due to oxidation, and the 
lack of purity of natural phospholipids 113. 
 
Ethosomes 
Ethosomes are another recently developed vesicular systems able to penetrate the mammalian skin when applied both under 
occlusive and non-occlusive conditions 110,114–116.   
 
Figure 2. Schematic representation of various types of L-NVs. (A) Conventional liposomes; (B) Transfersomes; (C) Niosomes; and (D) Ethosomes. 
Reproduced from Ref. 117 with permission from Frontiers Media S.A. 
 
As transfersomes, ethosomes are composed by phospholipids and an edge activator, based in this case on alcohols such as 
ethanol or isopropyl alcohol, used at high concentrations (Figure 2d) 118. Ethosomes size can be modulated from nano to micron 
range, and can be obtained either unilamellar or multilamellar vesicles 118,119. The high penetration achieved with these new 
vesicular systems are not well understood, although the high permeation is attributed to the high content of alcohols, since 
ethanol is a well know penetration enhancer that affects the intercellular region of the stratum corneum 120. Several works using 
ethosomes as carriers have been shown good results both in vitro and in vivo 69,92–94. For example, ethosome formulation 
containing psoralen has showed promising results for the treatment of vitiligo and psoriasis 121. Transdermal delivery with the 
ethosomal formulation showed increase permeation and skin deposition of psoralen 122. 
 
Sphingosomes 
The low stability of vesicular systems, such as liposomes and niosomes, has also prompted the researchers to develop other new 
vesicular system with improved stabilities, called sphingosomes. These new vesicular systems are composed by natural or 
synthetic sphingolipids and/or Chol. Sphingosomes can have vesicles size from nano to sub-micron range, and the membrane 
lamellarity include both unilamellar and/or multilamellar 123. The most commonly used sphingolipids are hexadecasphinganine, 
sphinganines, lysosphingomyelins, lysoglycosphingolipids, glucuronosphingolipids, phosphoglycosphingolipids, among others. 
Sphingosomes show several advantages that include better resistance to hydrolysis than liposomes and better drug retention. 
Sphingosomes have showed promising results in vitro and in vivo for the delivery of several drugs 124,125. For example, 
sphingosomes loaded with vinorelbine as an anti-mitotic agent have showed promising results in vivo, improving the drug 
retention, and also increasing their antitumor activity 96. In addition, they can be administrated by different routes, such as 
intravenous, intramuscular, subcutaneous, and intra-arterial. Also, the vesicular membrane of sphingosomes can be tuned with 
specific ligands to achieve active targeting. However, these vesicular systems show some limitations both related to their cost, 
because sphingolipids are very expensive, and to their poor entrapment efficiency 113.  
 
Ufasomes 
Ufasomes were first described in 1973 by Gebicki and Hicks, as vesicular systems composed by unsaturated fatty acids such as 
oleic acid and linoleic acid. Nowadays these vesicles are also made of saturated fatty acid such as octanoic acid and decanoic acid 
along with some surfactants 126. Ufasomes form vesicles with size between nano and sub-micron range, and can be unilamellar 
and/or multilamellar 126. Ufasomes have some advantages over convention liposomal formulations, since they show an improved 
stability, better entrapment efficiencies for both hydrophilic and hydrophobic drugs, and their membrane components are 
cheaper and more available 127–129. Ufasomes are therefore potential carriers for topical delivery of pharmaceuticals and 
biopharmaceuticals 97–99,130. For example, ufasome gel formulations loaded with dexamethasone as anti-inflamatory drug 
showed promising results in vivo after topical admimistration in Carrageenan induced rat paw edema model. The transdermal 
permeation of the drug-loaded ufasome gel was higher than the plain drug and plain gel. Moreover, a significant reduction of 
edema was observed, when drug-loaded ufasome gel was used, compared to the commercial product. Nevertheless, ufasomes 
have some issues related to their skin toxicity and their low entrapment efficiency of hydrophilic drugs 98,130. 
 
Pharmacosomes 
Pharmacosomes are colloidal dispersions composed mainly by phospholipids, where drugs are covalently bound to the lipid 
131,132. Pharmacosomes are also referred as phytosomes, when the drug is an herbal active ingredient 133,134. Pharmacosomes 
were developed in order to improve the encapsulation efficiency of polar drugs, which are difficult to encapsulate with high 
efficiencies in conventional liposomal formulations 132. These colloidal dispersions can exist as vesicular, micellar or hexagonal 
assemblies, depending on the chemical structure of the drug-lipid complex, and the size of the assemblies obtained are in the 
nano and micro range 131. The physicochemical stability of pharmacosomes depends mainly on the physicochemical properties of 
the drug-lipid complex 135. Pharmacosomes can pass through biomembranes efficiently and possess several advantages over the 
vesicular systems previously described, since the drug is covalently bounded to the lipid, the encapsulation efficiency is 
increased, the leakage of drugs is avoided, there is no need of additional steps to eliminate the free drug, and the drug release is 
not affected by the membrane fluidity 136,137. Several drugs like taxol, amoxicillin, dermatan sulphate have shown increased 
therapeutic effect when formulated within pharmacosomes 131. 
 
Virosomes 
Virosomes are hybrids of liposomes and viruses, which integrate fusogenic viral envelope proteins into the lipid membrane of 
liposomes 138,139. Virosomes form vesicles with size in the nano and sub-micron range, and can be unilamellar and/or 
multillamellar. Virosomes are promising candidates for the delivery of both pharmaceuticals and biopharmaceuticals, since the 
fusogenic viral proteins allow them to penetrate into cells, and escape from the endosomes, delivering their cargo directly into 
the cytoplasm of the cells 140,141. Several works have been shown promising results both in vitro and in vivo using virosomes as 
carriers 102,142–144. Moreover virosomes have been used as vaccine carriers and as adjuvant systems, since they have shown to 
improve cell-mediated and humoral immune response, generating long-term immunity against pathogens. For example, 
virosomes loaded with specific melanoma-associated antigen, gene or RNA induce protective immunity in a mouse-melanoma 
model 145. Despite all the advantages that virosomes have showed, safety concerns are related with their use since the viral 
proteins produce some immunogenicity; additionally, they have shown poor stability 146. 
 
Quatsomes 
Quatsomes are unilamellar nanovesicles constituted by quaternary ammonium surfactants and sterols in defined molar ratios 
147,148. These colloidal structures are stable upon long storage such as several years, their morphology do not change upon rising 
temperature or dilution, and they show outstanding vesicle to vesicle homogeneity regarding size, lamellarity and membrane 
supramolecular organization 147,149,150. It is important to highlight that the unilamellarity of quatsome-like structures and their 
homogeneous morphology make these systems ideal for the precise functionalization of their membranes, which is very 
important for a robust and efficient drug targeting 151–153. Another important characteristic of quatsomes is that their membrane 
components are not expensive and are available at pharmaceutical grade. For instance, the surfactants forming the quatsome 
membrane are widely used as disinfectants, algaecides, preservatives, detergents and antistatic components 154. This confers to 
quatsomes an additional antibacterial feature 74. Therefore quatsomes fulfill the structural and physicochemical requirements to 
be a potential encapsulation platform for site specific delivery of both hydrophilic and lipophilic therapeutic and diagnostic 
actives. These vesicular systems are promising alternative to cationic vesicles prepared with pure cationic lipids, which have 
showed high cytotoxicity and lower stabilities 155,156. Quatsomes-like structures have been formed using different quaternary 
ammonium surfactants such as cetrimonium bromide (CTAB), myristalkonium chloride (MKC) and cetylpyridinium chloride (CPC) 
and different sterols such as cholesterol and β-sitosterol 150. In a recent study, quatsomes were evaluated for their antimicrobial 
activity in an in vitro S. aureus biofilm model. Quatsomes prepared with an antiseptic quaternary ammonium compound CPC and 
Chol have showed good anti-biofilm capacity without no adverse effect on the cells 74. Furthermore, it is worth mentioning that 
recently, quatsome-like structures have been produced using single-chain anionic surfactants instead of quaternary ammonium 
surfactants.  
Methods of preparation 
Physico-chemical properties of nanovesicles, including size, morphology, lamellarity as well as encapsulation efficiency (EE) are 
of utmost importance in order to achieve optimal performances in their final application as biofunctional materials. In general, 
these properties are strongly affected by the system composition and by the synthetic approaches exploited for their production. 
In the literature several methods for preparing lipid-based nanoparticles are described and they are usually categorized as 
conventional or novel. Generally, conventional approaches are easy preparation methods, especially at laboratory scale, but they 
usually fail when scaled-up up to industrial level. Complex, time- and chemical-consuming purifications are usually required in 
order to remove all the agents used in the phase of production and this, in turn slows down the production chain and raise up 
the processing costs, making conventional strategies not reliable at industrial level. Other issues are related to the harsh 
conditions applied during the production. Thus, often high mechanical stress and temperature are necessary during their 
processing, which can result in the degradation of labile biomolecules, such as proteins, enzymes, nucleic acids. Furthermore, the 
control over materials properties is not fully reliable as well as the reproducibility among different batches. Finally, the 
environmental constraints on production process are nowadays more restrictive, forcing the industries to drive towards more 
efficient and eco-friendly manufacturing process. For all these reasons, new manufacturing processes have been developed in 
the last years using techniques based on microfluidic or CF technologies, among others. These approaches are easy to scale-up, 
but can require special equipment, which in turn can rise up the costs. Financial aspects are also needed to be evaluated case-by-
case 157,158,67. In the following, the most used conventional and novel approaches will be presented, with a stronger emphasis on 
novel approaches exploiting CF-based technology. Most of the examples here presented will refer to liposomes, because only 
few examples of non-liposomal lipid-based vesicles are available in the literature. However a general trend can be observed: all 
these preparation methods may be exploited for the production of non-liposomal nanovesicles. In Table 2 the advantages and 
disadvantages of the various preparation methods here described are reported. 
 
Table 2. Advantages and disadvantages of nanovesicles preparation methods. 
 
Preparation Methods Advantages Disadvantages 
Conventional Methods • Easy at lab-scale 
• Low yield 
• Low reproducibility 
• Many post-formation steps Very 
heterogeneous vesicles 
• Low encapsulation efficiency 
• Not scalable at industrial level 
Compressed Fluid-based 
Technologies 
• Milder conditions (stirring, temperature, chemicals) 
• One-pot technology (no post-formation steps) 
• Homogeneous Nanovesicles 
• High control of materials properties 
• High throughputs & Reproducibility 
• Sterility 
• Easy to scale-up 
• Safety (high-pressure) 
• Solubility of lipids in CFs 
• High capital cost of the equipment 
Microfluidic 
• Homogeneous Nanovesicles 
• High control of materials properties 
• Fast and cheap process 
• Harsh shear conditions 
• Not easily scalable at industrial level 
Other non-conventional 
methods 
• Homogeneous Nanovesicles 
• High control of materials properties 
 
• Low reproducibility 
• High cost of production 
• Not easily scalable at industrial level 
Conventional Preparation Methods 
 
Conventional methods for vesicles production consist of a production step, during which vesicles are formed as dispersion in 
aqueous phase, and a few postformation steps, during which the desired structural characteristics, in terms of size, morphology 
and lamellarity, are achieved. There is a wide variety of conventional methods to prepare liposomes, including thin-film 
hydration, reverse-phase evaporation, solvent injection, and detergent dialysis 65,159–161 With the majority of these techniques, 
after the production step, big LUVs, MLVs and GUVs are obtained. In these methods the self-assembly of lipid vesicles typically 
occurs within environments with characteristic dimensions of millimeters or centimeters, which results in local concentration 
fluctuations of lipids and payloads, i.e. heterogeneity. In order to alter particle size and minimize the polydispersity, 
postformation steps are needed such as sonication 162 extrusion 163–165, and high-pressure homogenization 166,167 methods to end 
up with a homogeneous dispersion of SUVs. A schematic representation of the conventional processes is reported in Figure 3. 
Mechanical forces are applied for disrupting large MLVs into small membrane patches that ultimately form SUVs. The need for 
using additional mechanical processing limits to a great extent the application of conventional methods for the encapsulation of 
fragile molecules due to the extreme conditions usually applied. The thin lipid film hydration method was developed by Bangham 
et al. for liposomes production and it has been extensively used since then for the production of other L-NVs and micelles 168,169. 
Lipids are dissolved in an organic solvent, which is then evaporated. A thin lipid film is created in a round-bottom flask and the 
complete removal of the solvent is achieved by freeze-drying. The nanovesicles are formed after re-hydration of this thin-film 
with an aqueous solution. Multiple freeze/thaw cycles are often requested in the latter step. Depending on the conditions of re-
hydration, nanovesicles with different physico-chemical properties are obtained.  
 
Figure 3. Schematic representation of the most common conventional 
synthetic approaches for L-NVs production. 
 
As already mentioned, in order to obtain particles with smaller 
sizes and higher homogeneity, some additional steps need to be 
performed 170. In Figure 4 it is shown a schematic representation 
of the thin film hydration method. Although it is a simple 
technique at laboratory scale, it is not easily scalable to 
industrial level since its reproducibility and yield are low, 
requiring multiple time- and energy-consuming steps to reach 
the final product. Another technique extensively used for L-NVs 
production is the reverse phase evaporation method. In this 
method the lipids are first dissolved in an organic solvent, which 
is then evaporated in order to form a lipid film. This film is then 
re-dissolved in ether or isopropyl ether. Afterwards, an aqueous phase, carrying the drug to be loaded in, is added to the organic 
phase and the two phases are mixed where inverted micelles or water-in-oil emulsion are formed.  
The organic solvent is gently evaporated under a reduced pressure and a dispersion of nanovesicles in water is obtained 160. 
Sometimes a further purification step is requested, in order to completely remove the organic solvent. The reverse-phase 
evaporation method presents higher encapsulation efficiencies than thin film hydration; however it is limited by the solubility of 
the lipids in the organic phase and the subsequent removal of the solvent from the final preparation. The solvent injection 
technique has been also exploited in order to form L-NVs. In this case an organic solution of lipids is directly injected in an 
aqueous solution. The rapid dilution of the organic solvent in the aqueous phase causes the formation of nanovesicles. 
Depending on the solvent used, the technique is slightly modified. For example when ether is used, the aqueous phase is 
warmed up to 60 ºC before performing the injection.  This technique really often leads to heterogeneous vesicles, both in terms 
of size, morphology and lamellarity 171,172. Finally, in the detergent depletion method, the lipids are first dissolved into micelles, 
which act as a template and then an aqueous phase is added. When the surfactant is removed, the lipids start to coalesce and 
the vesicles are formed. Usually large unilamellar vesicles are formed with this method and problems associated with detergent 
removal, which include low trapping efficiency and length of preparation, limit the use of detergent-based techniques in 
producing LUVs 173–175. 
 
Novel Preparation Methods 
Compressed Fluid-based Technologies Compressed Fluid (CF)-based technologies have recently gained importance for the 
Figure 4. Schematic representation of the thin film hydration method. 
production of L-NVs by (i) showing high throughput of high quality, homogeneous products; (ii) being a promise for the 
industrialization of such materials and (iii) accommodating the principle of green chemistry.  
The unique features of CFs in terms of gas-like mass transfer properties and liquid-like solvent power together with their 
pressure-tunability are the keys for the successful performances of CF-based technologies. 176,177 In fact, the prominent 
properties of CFs can be tuned by the mean of the pressure: pressure variations are mechanical perturbations that travel at the 
speed of sound, propagating quickly and homogeneously across the medium leading to large but uniform modifications of the 
fluid density and solvent power. When used as a trigger for nanoparticles formation, this fast and homogeneous modification of 
the fluid properties favours the achievement of high quality, uniform nanomaterials without the need for postformation steps as 
in conventional methods 149,159,176,178,179. Such feature is missed in other approaches, where the triggers for nanoparticles 
formation are changes in the temperature or composition, which do not propagate quickly and homogeneously within the 
medium, causing gradients of concentration inside the reactor and leading to heterogeneous nanoparticles. CF-based 
technologies allow to reduce the high mechanical stress due to the high stirring as well as the high operating temperatures used 
in conventional processes, which in turn can degrade labile compound 177,178,180. Moreover, the extensive use of organic solvents 
or other delicate chemicals is reduced by CFs, improving the toxicological profile of the particles produced; CF-based 
technologies  are often one-pot production technologies and they can also provide sterile operating conditions 159,181. The most 
widely used CF is CO2, which is nontoxic, non-flammable and easy recyclable. The moderate critical parameters of CO2 (Pc = 7.4 
MPa; Tc = 304.1 K) together with its low price and high availability make also CO2-based technology very attractive from an 
economical perspective. Most of the methods using compressed CO2 for L-NVs production involve the formation of a mixture of 
this dense gas, the vesicle membrane constituents, and an organic solvent at a certain pressure and temperature; vesicles are 
usually produced upon contact between this organic phase and an aqueous phase. Various CF-based technologies have been 
developed for the generation of L-NVs by changing the experimental procedure, parameters, and equipment resulting in a large 
variety of vesicular systems with differentiated characteristics. Generally, CF can act either as a solvent or as anti-solvent or as 
co-solvent, depending on the solubility of the solutes in the CF 176,181,182. More in detail, the CF is used as solvent when all the 
components are likely soluble in it; in this case, the organic solvent acts as a co-solvent, when present. When the CF is used as 
anti-solvent, it means that the components are not soluble in it, so first they are dissolved in the organic solvent and then the CF 
is added to the mixture for triggering the precipitation of solutes. Finally, when the CF is used as a co-solvent, all the components 
are dissolved in a mixture of the organic solvent and the CF, which in turn increases the solubility of the solutes in the organic 
solvent 159,176,178,179. In Table 3, the CF-based technologies here reviewed are summarized, by defining the role of CF and if the 
organic solvent is present or not. Also, the typical operation conditions used are reported, as well as the kind of SUVs produced. 
As far as we know, Depressurization of an Expanded Liquid Organic Solution-SUSPension method (DELOS-SUSP) is the only CF-
based technology that have been already used for the production of non-liposomal L-NVs. In particular, a variety of Quatsomes 
have been generated by exploiting this method. The injection and decompression methods described by Castor and Chu in 1994 
183 have been the first CF-based techniques developed for the formation of liposomes (Figure 5). While in the injection method, a 
mixture of lipid, organic co-solvent, and compressed gas is injected through a nozzle into an aqueous solution, the 
decompression method involves a mixture of lipid, organic co-solvent, compressed gas, and aqueous solution being 
decompressed into air through a nozzle to form the vesicles. The major distinction between the two methods is the “place” in 
which occurs the contact between the organic and the aqueous phase. The authors have studied the effect of the nozzle size on 
the liposomes size and they have found that the smaller is the size of the nozzle, the smaller are the liposomes. The injection 
method is more suitable for the processing of labile compound because of the absence of high shear forces. The authors claim 
that the injection and decompression methods are capable of producing substantially solvent-free, sterile and pharmaceutical 
grade vesicles with narrow particle size distribution 184. The liposomes generated by these methods  have also shown excellent 
colloidal stability over a period of 6 months 185. However, for the clinical development of liposomal drugs, a shelf-life of more 
than 12 months needs to be proved. This method has shown to be well suited both for hydrophobic and hydrophilic drugs 
encapsulation, such as taxoids, doxorubicin, michellamine B, vincristine and cisplatin 186.  
 
Table 3. Summary of CF-based technologies reviewed. CO2 role, presence or not of any organic solvent, temperature (T) and pressure (P) and 
kind of SUVs produced are reported. 
Method (year, ref) CO2 role Org. Solv. T (ºC); P (MPa) SUVs 
(refs) 
Injection method (1994, 183) Solv. Yes 60; 20 Liposomes 184–186 
Decompression method (1994, 183) Solv. Yes 60; 20 Liposomes 184–186 
Superfluids Phospholipids Nanosomes (2005, 187,188) Solv. Yes 10-60; 6.8-34.5 Liposomes 187,188 
Supercritical Liposomes Method (1994,189–191) Solv. Yes (low amount) 60; 25 Liposomes 
189–191 
Supercritical Reverse Phase Evaporation Method (2001, 181) Solv. Yes 60; 20 Liposomes 181,192 
Improved Supercritical Reverse Phase Evaporation 
Method (2006, 193) Solv. No 60; 20 Liposomes 
193 
Depressurization of an Expanded Liquid Organic Solution-
SUSPension (2008, 194) Co-solv. Yes 35;10 
Liposomes 149,195,196 
Quatsomes 147,149,194,195 
Depressurization of an expanded solution into aqueous 
media (2004, 197) Co-solv. Yes 22; 4-5.5 Liposomes 
197,198 
Rapid Expansion of Supercritical Solutions (1984, 199) Anti-solv. Yes 65; 30 Liposomes 199–202 
Supercritical Anti-Solvent (1998, 182) Anti-solv. Yes 30-60; 8–33 Liposomes 182,203–211 
 
 
Figure 5. Scheme of the apparatus used in the injection/decompression 
methods. Reproduced from Ref. 158 with permission from Future 
Medicine Ltd.  
 
The injection method produced liposomes with superior 
physical stability and efficiency of drug encapsulation than 
those of conventional sonication methods 186. The potential 
disadvantages of the injection and decompression methods are 
the use of nozzles, the high capital cost of the equipment, and 
the high process pressure and temperature requested. 
Afterwards, a number of variants of the 
injection/decompression methods have been proposed by the 
same authors among the years, trying to generate smaller and 
unilamellar vesicles with a lower polydispersity on one side and 
to improve the EE on the other side. In the 2005, the 
SuperFluids Phospholipids Nanosomes (SFS-CFN) were 
developed 187.  
Small and uniform liposomes (up to 200 nm) were produced by 
this method using process conditions of at 60 ºC and 24 MPa, 
granting a homogeneous dissolution of the materials in the dense gas/co-solvent mixture, using a recirculation loop. In-vivo 
studies were performed using these liposomes containing paclitaxel and they showed that this formulation had a significantly 
greater effect on the cancer cells than the conventional therapeutic formulation 187.  
A further implementation of these methods arrived in 2010, when Castor invented an improved process to co-encapsulate 
hydrophobic and hydrophilic drugs into the nanovesicles. In this method, a phospholipid and hydrophobic drug solution are 
dissolved in the dense gas with (or without) a co-solvent. Afterwards, the phospholipid and hydrophobic drug solution is 
depressurized in an aqueous solution containing the hydrophilic drug, resulting in the formation of uniform liposomes that 
encapsulate hydrophobic and hydrophilic drugs. This method has been proven to be very useful for combination drug therapies 
188. In general, with the injection and decompression methods, as well as their variants, the size and characteristics of 
nanovesicles depend on the process parameters and material properties, including the size and design of the decompression 
nozzle, pressure, the rate of decompression, interfacial forces, charge distribution and the nature of the compound being 
encapsulated. Frederiksen et al. have developed the supercritical liposome method 190 in the 1994. This method is similar to the 
injection method, but in this case the required pressure is higher (up to 25 MPa) and the amount of co-solvent used is lower (up 
to 15-fold less). The yield of the process is around 80% and most of the liposomes produced are small unilamellar vesicles, having 
sizes between 20-50 nm. A small fraction of MLVs are also formed. However, their EE was reported to be approximately 20% 
lower than that achieved using conventional methods 189. In the supercritical liposome method phospholipids and Chol are 
dissolved into supercritical CO2 in the presence of ethanol (5-6%) and ethanol and CO2 are recirculated many times in order to 
achieve the complete dissolution of the lipids. Then, the solution is quickly expanded over an aqueous solution containing the 
hydrophilic drug to be entrapped in. The main difference between this method and the injection method is the fact that here 
before the expansion, the two phases are in touch inside a capillary. The size of the capillary, i.e. its surface area, strongly 
influences the size of the liposomes and EE 189,191. As stated in its name, this method has been developed for liposomes 
production, but it can be also used for non-liposomal L-NVs. 
Otake et al. developed the supercritical reverse phase evaporation 
method (scRPE) in 2001 181 (Figure 6). The basic concept of this 
method is similar to that of the conventional reverse-phase 
evaporation method. Thus, lipid, organic co-solvent, and 
compressed gas are combined in a stirred, variable volume cell at 
a temperature higher than the phase transition temperature of 
the phospholipid. An aqueous solution is then slowly introduced 
into the cell. The system turns to a microemulsion when the 
amount of water introduced is low (DPPC forms reverse micelles 
in the water/CO2 microemulsion), while the microemulsion turns 
to a macroemulsion as the amount of introduced water increases. 
The pressure is then released, and vesicles are formed as CO2 
evaporates from the aqueous phase upon depressurization. The 
main difference with respect to the decompression method is the 
absence here of a sprayer. If compared with the Frederiksen’s method, the scRPE method is simpler and requires less CO2.  
LUVs (0.1-1.2 µm) have been formed with this technology. The mechanism of formation of the vesicles is pretty complicated. 
Imura et al. studied the mechanism of liposome formation by scRPE. They found that the colloidal structures of the emulsions 
(water/CO2 or CO2/water) obtained before the liposome preparation directly influences the physicochemical properties of the 
liposomes, such as their particle size, EE and lamellarity 212,213. Liposomes modified with lipopeptides have been also prepared by 
the scRPE method. In particular, bovine serum albumin has been used a model drug in this study in order to verify if this method 
allow to increase the EE of the protein. The encapsulation was higher (up to 70%) than those obtained using the conventional 
Bangham’s method, and approximately 90% of the entrapped drug was retained for up to 48 h in the produced liposomes, 
whereas no drug remained in liposomes produced using the Bangham’s method after 48 h 192. Owing to the single-step nature of 
this method, scaled-up liposome production is possible. Furthermore, Otake et al. have reported an improved version of scRPE 
method named as ISCRPE, which does not use any organic solvent. In this case a pure CO2/water emulsion is formed at 60ºC and 
2 MPa. The drug-loading efficiency and stability are improved compared with the scRPE method. A key parameter of this version 
is the depressurization rate; the slower is the depressurization, the higher is the control over material properties. The authors 
also have observed that the EE is increased when longer alkyl chain or unsaturated lipids are used. Furthermore, the shelf-
stability of such liposomes is longer than that of liposomes produced by Bangham’s or Frederiksen’s methods. The ISCRPE is very 
simple compared with the scRPE method and it is also scalable 193. In 2008, a CF-based method, called Depressurization of an 
Expanded Liquid Organic Solution-SUSPension (DELOS-SUSP) for the preparation of colloidal nanomaterials was developed 194. 
This method was an intensification of DELOS (Depressurization of an Expanded Liquid Organic Solution) process, with which 
micron-sized and submicron-sized crystalline particles with high polymorphic purity were prepared  214,215. DELOS-SUSP method, 
which involves the depressurization of a CO2-expanded liquid solution of lipids into an aqueous phase, uses a very simple set-up 
and mild conditions of pressure (10 MPa) and temperature (35 ºC) than the above described methodologies. Using this method 
the straightforward one-step preparation of L-NVs with controlled size distribution, uniform shapes, and good shelf-stability has 
been achieved 195. Briefly, the DELOS-SUSP method (Figure 7) consists in loading a solution of the membrane lipid components 
and the desired hydrophobic bio-actives in an organic solvent (e.g., ethanol) into a high-pressure autoclave, previously driven to 
the working temperature (Figure 7a). The reactor is then pressurized, with a large amount of compressed CO2 until reach the 
working pressure (10 MPa) (Figure 7b). Finally in the third stage, the vesicular conjugates are formed by depressurizing the 
resulting CO2-expanded organic solution over an aqueous phase, which might contain water soluble surfactants and hydrophilic 
bio-actives (Figure 7c) 195. In this last step, a flow of N2 at the working pressure is used in order to push down the CO2-expanded 
solution and to keep constant the pressure inside the reactor. A worthy notorious point is that the depressurization is simply 
performed by the mean of a valve, without the need of any special nozzle, reducing the complexity of the plant as well as the 
equipment cost. The CO2 here acts as co-solvent, and its evaporation from the organic expanded solution during the 
depressurization stage produces a fast, large and homogeneous cooling responsible for the high vesicle-to-vesicle structural 
homogeneity in comparison to that reached by conventional methods (Figure 8). 
DELOS-SUSP technology has shown to be a robust productive process both for the production of liposomes as well as other kinds 
of L-NVs, in particular quatsomes 195,196. Many membrane components have been processed by DELOS-SUSP, such as 
phospholipids, sterols, surfactants. Also, both hydrophobic and hydrophilic bio-actives have been simultaneously loaded in L-NVs 
by DELOS-SUSP, showing that DELOS-SUSP is a viable platform for the preparation of nanovesicle-bioactive conjugates. For 
instance, multifunctional conjugates composed by liposomes functionalized with RGD peptides and encapsulating α-
Galactosidase A (GLA) enzyme were successfully prepared using the DELOS-SUSP 195. These nanovesicle conjugates showed 
higher efficacy, in relation to the free proteins, in pre-clinical in vitro and in vivo tests 196.  
 
Figure 7. Schematic representation of the DELOS-SUSP method for the 
efficient preparation of multifunctional nanovesicle-bioactive hybrids. 
The whole procedure includes the loading (a) of an organic solution of 
the lipidic membrane components and the desired hydrophobic active 
compounds/molecules into an autoclave at a working temperature (Tw) 
and atmospheric pressure; the addition of CO2 (b) to produce a CO2- 
expanded solution, at a given XCO2, working pressure (Pw), and Tw, 
where the hydrophobic active and membrane components remain 
dissolved; and finally, the depressurization (c) of the expanded solution 
over an aqueous solution, which might contain membrane surfactants 
and hydrophilic biomolecules, to produce an aqueous dispersion of the 
nanovesicle-bio-active(s) hybrids. Reprinted with permission from Ref. 
195 (I. Cabrera et al., Nano Lett., 2013, 13, 3766–74). Copyright 2013. 
American Chemical Society.  
 
Furthermore, various kinds of molecules have been successfully 
integrated in quatsomes by the means of DELOS-SUSP, either 
by directly processing sterol-like molecules previously modified 
with a (bio)-active molecule or by loading in the reactor 
hydrophobic (bio)-active molecules and self-assembling them together with the sterols and the surfactants.  
A similar method to DELOS-SUSP, named Depressurization of an expanded solution into aqueous media (DESAM) has been 
developed by Meure et al. for liposomes production. The lipids are dissolved in an organic solution, that is then expanded by a 
dense gas. A rapid depressurization occurs at the end of the process over water and the solution was left bubbling for one hour. 
During this time, also evaporation of the organic solvent was obtained in the vessel, heated and agitated by CO2 
197.  
In this method liposomes form instantaneously after the injection of the expanded liquid in water solution, thanks to lipid 
spontaneous organization in a bilayer structure that is the favoured configuration and allows to reduce the contact with water of 
the not-polar lipids chains. Vesicle dimensions can be related to the high turbulence generated during injection and 
decompression of the expanded liquid. Liposomes with diameters in the range of 50-200 nm have been produced using this 
technology. However, the major limitation of this technique is the low entrapment efficiency. This process has been designed to 
use moderate temperatures and pressure. Temelli et al have developed a new CF-based method, based on the modification of 
ISCRPE and DELOS-SUSP processes for the production of small and unilamellar liposomes. The main advantage of this method is 
to be free of any organic solvent 216. CF has been used also as anti-solvent for the preparation of L-NVs. In particular, Rapid 
Expansion of Supercritical Solutions (RESS) and Supercritical Anti-Solvent (SAS), methods exploit CO2 as anti-solvent; these 
methods were initially developed for processing a wide variety of difficult-to-comminute solids and then they have been 
modified for the preparation of L-NVs. Thus, RESS started in 1984, when Krukonis showed its potential for the first time 199 and 
since then, several applications have been conducted. In the RESS process, the solute or solutes are solubilized in a dense gas at 
high pressure (>20 MPa) and this solution is then depressurized through a heated coaxial nozzle into a precipitation chamber at 
supersonic speed. This rapid expansion (<10-5 s) of the solutions inside the chamber leads to a super saturation of the solute and 
a subsequent precipitation of solute particles with narrow particle size distributions 200. RESS technology has been used for 
processing drugs, polymers as well as for L-NVs preparation. Depending on the requirement of the product, various 
modifications of the process have been developed. In particular, the RESS process has been successful for polymer nanoparticles 
formation, but it has shown its limits for lipid-based nanoparticles production because lipids are not completely soluble in pure 
compressed CO2.  
 
Figure 8. Cryo-TEM micrograph images of quatsomes produced by DELOS-
SUSP (a) and thin film hydration method (b). Particle size distribution curves 
measured by dynamic light scattering of disperse systems (c). 
 
Wen et al. introduced some modifications to the conventional RESS 
process to produce liposomes: PC, Chol, and the essential oil of 
Atractylodes macrocephala Koidz were dissolved in compressed CO2 
and ethanol, and after the system reached the equilibrium, a buffer 
solution was injected by a syringe pump into the dissolved solutes. 
The final mixture was then expanded through a nozzle into the 
collector where liposomes with (i) spherical morphology, (ii) narrow 
size distribution with an average size of 173 nm, (iii) EE of 82 %, and 
(iv) ethanol amount of 15% 201. Zhang et al. also synthesized 
liposomes exploiting the RESS process; using phospholipids and Chol that were dissolved in a sirolimus solution containing water 
and Tween®-80, and then ethanol was added to the solution. CO2 was then added, obtaining uniform and medium sized with a 
narrow size distribution nanovesicles 202. Importantly, this modified RESS process shows good prospects for the scaled-up 
production of liposomes.  
The first example of SAS process is referred to Kikic in 1998 182. A solution composed of the solute and of the organic solvent is 
sprayed into a continuous phase composed of the supercritical fluid. The latter acts  as  an  anti-solvent  for  the  solute  but  as  a  
solvent with  respect  to  the  organic  solvent.  The  simultaneous  dissolution  of  the  supercritical  fluid  in  the liquid droplets 
and the evaporation of the organic solvent  in  the  supercritical  phase  induce  a  super-saturation of the solute into the liquid 
phase and then  to its  precipitation. In the SAS process, the final processed material is deprived of any traces of organic solvents. 
The advantage of SAS over other methods is that rapid contact between the two media (anti-solvent and lipid solution) can be 
achieved, which speeds up the process of nucleation and growth, resulting in the formation of smaller particles. More recently, 
Magnan et al. reported that SAS can be used for the production of liposomes using lecithin 203. Naik et al. developed a method to 
prepare docetaxel-entrapped PEGylated liposomes using the SAS technique that is suitable for large-scale industrial application. 
In this method, docetaxel, phospholipids and Chol are first dissolved in organic solvents (chloroform:methanol) and 
distearoylphosphatidyl ethanolamine–PEG is then added to prepare PEGylated liposomes. Liquid CO2 is then converted to a 
supercritical state, and the mixture is sprayed into a high-pressure vessel in which the pressure and temperature of the vessel 
are at steady state. The SCF-CO2 in the vessel allows mixing of the drug–lipid solution and precipitation of proliposomes with 
entrapped docetaxel. Hydration then converts proliposomes into liposomes. The liposomes obtained by this method are small, 
unilamellar and spherical, with a size range of 200–300 nm and an EE of approximately 80% was obtained. These formulations 
were completely free of residual solvents and the liposomes were stable for at least 3 months 204. Lesoin et al. have compared 
two methods to produce liposomes encapsulating a fluorescent marker: the SAS method and the Bangham’s one. Liposomes 
were prepared using micronized lecithins and they have been characterized in terms of size and EEs in order to compare the two 
methods. Liposomes formed from SAS show size distribution mainly bimodal, spreading in the range of 0.1–100 µm with EE 
between 10 and 20%. As concerns with the Bangham’s method, more dispersed liposomes were formed, EEs obtained were 
about 20%, and some problems of reproducibility appeared 207. Lesoin et al. have also introduced a new method called a 
continuous anti-solvent process in which micronization and hydration are performed in a single step 206,207 Very recently, RGD-
grafted PEGylated docetaxel liposomes were prepared using the SAS technique. Grafting of RGD to the PEGylated docetaxel 
liposomes significantly improved anti-proliferative activity compared with the free drug and PEGylated docetaxel liposomes. 
Although these RGD-grafted PEGylated docetaxel liposomes are still at an early preclinical stage, they may be a feasible 
treatment option for breast cancer treatment if future studies demonstrate that they have low toxicity, good bioavailability and 
high efficacy 205.  In 2011, Hwang et al. introduced a novel SCF-CO2 method based on the SAS technique to prepare liposomes in 
which a dried mixture of lipids, Chol and the drug of interest (Amphotericin B (AmB)) are coated with anhydrous lactose, a water-
soluble carrier. They compared these liposomes to the ones produced by conventional techniques. Liposomes obtained after 
homogenization were unilamellar and spherical in shape with an average diameter of 100 nm with an EE greater than 80%. SCF-
CO2 liposomes were found to be more stable than conventional liposomes for a test period of 1 month, leading the authors to 
propose the possibility of long-term storage of SCF-CO2 liposomes by lyophilization. A hemolysis study revealed that liposomal 
AmB prepared by the SCF-CO2 method was less hematotoxic than a commercial micellar formulation of AmB Fungizone® 
(Bristol-Myers Squibb, NJ, USA). This method could, therefore, be a superior alternative to the conventional Bangham’s method, 
and is well suited to the mass production of liposomes 208. Xia et al. investigated process parameters for the efficient preparation 
of liposomes encapsulating coenzyme Q10 using the SAS technique 209. Karn et al. 210 adopted the method invented by Hwang et 
al. 208 to prepare liposomal cyclosporine A (CsA). The differences between liposomes prepared using the SCF-CO2 and 
conventional modified Bangham’s methods were thoroughly investigated, revealing that liposomes prepared using SCF-CO2 
were physically and chemically more stable than liposomes prepared using the conventional method 206–208. The SCF-CO2 
liposomes were smaller, uniform and more spherical than the liposomes prepared using the conventional method. Additionally, 
a nontoxic organic solvent (ethanol) was used, which evaporated completely before hydration. 
 
Other Non-conventional Preparation Methods 
Over the last years, microfluidic technologies have been mainly developed and used as tools in chemical synthesis and biological 
analysis. Nevertheless, it has received an increasing interest as a novel platform for the preparation of nano- and microparticles 
217. It is a versatile technology that enables a precise control and manipulation of fluids and liquid flows in channels at the 
micrometer scale, allowing the implementation of the mixing process into small planar chips and devices. Due to its 
characteristics, it can provide a rapid and tunable mixing with homogenous reaction environments, and a high-throughput 
experimental platform 217,218. Because of the exquisite control of flow and mixing conditions, it has been applied for producing L-
NVs, altering particle size and improving homogeneity of particle size distributions as well  219–221. The application of microfluidics 
to the synthesis of nanovesicles in novel lab-on-a-chip based devices can dramatically reduce the time required for sample 
preparation as well as the costs associated with experimental work 218.  
 
Figure 9. Microfluidics technology to produce liposomes with high 
precision and efficiency. Cross-flow where the aqueous buffer is 
introduced in a different axis to the lipids in organic solvents.  
 
Jahn et al. (2004 and 2007) developed a microfluidic 
hydrodynamic focusing (MHF) method for controlled liposome 
formation. A stream of aqueous solution is injected in a small 
channel (up to 500 µm), resulting in a laminar flow. A 
perpendicular flow of lipids dissolved in an organic phase is 
injected in the channels, mixing with the aqueous phase. The 
organic phase is diluted and the lipids self-assembled into vesicles (see Figure 9). The size, morphology and lamellarity of the 
vesicles are strongly affected by the process parameters as the size of the microchannels, the concentration of the lipids, the 
ratio between the two flows, and the magnitude of flows 222,223. The NanoAssembler platform and the NanoAssembler Scale-up 
platform developed by Precison Nanosystems, INC., Canada, have produced liposomes both at the lab-scale and at clinical-scale 
using the microfluidic technology 218. In fact, microfluidization can be scaled up by increasing the number of channels in a parallel 
configuration. Nevertheless, it can be problematic for the processing of thermo-labile compounds due to the high shears 
developed in this process. Also, some processing problems, such as channel blocking, might take place making difficult to 
translate to industry. Another aspect to take into account for this kind of sophisticated equipment is the required cleaning step 
after each batch production. A GMP-compliant procedure should include cleaning and cleaning validation procedures to avoid 
batch-to-batch or product-to-product contamination. Up to now there is not clear whether at industrial scale it would be 
possible to ensure the cleanliness of multiple nanometer-sized channels. Apart from the techniques based on microfluidics and 
CF technology that present promise features, other types of non-conventional methods for preparing nanovesicles have been 
developed and proposed in the last years. Some of these techniques are based on the use of sophisticated templates over which 
the vesicles are formed, aiming to achieve size-controlled and monodispersed colloidal dispersions 224–227. For example, 
DNA/protamine polyplexes were used as templates for the production of vesicles smaller than 200 nm using the layer-by-layer 
method intended for gene delivery 225. In another study, DNA nano-octahedron obtained through DNA engineering and inspired 
in the shape of virus, were used as templates for the preparation of lipid-based vesicles with 76 nm on diameter 227. Yang et al, 
produced monodisperse SUVs of different sizes and compositions using the DNA origami technique. The DNA-origami 
rings/nanotemplates served as an exoskeleton inside which the SUVs are formed, contrary to the majority of other techniques 
using templates as endoskeleton. Nanotemplates of 29, 46, 60, and 94 nm originated liposomes of ~22, 45, 58 and 94 nm, 
presenting a high monodisperse distribution with at least 85% of the particles falling within the expected size range, and a small 
percentage of particles with smaller sizes 224. Despite the promising results, the scalability of these techniques for drug delivery 
purposes could be impaired by the high costs of DNA nanotemplates’ production. Other method that has showed to produce 
nanovesicles is based on the freeze-drying of emulsions 228–230. The method is based on the dissolution of hydrophilic 
components of the formulation (like drugs and cryoprotectans) in the water phase, while the hydrophobic components (like 
drugs and lipids) are dissolved in an organic solvent. After emulsification, the formulation is freeze-dryed to eliminate the liquid 
phase and the vesicles form by suspending the obtained dry powder in an aqueous solution (Figure 10). For example, PC:PS:Chol 
unilamelar liposomes smaller than 200 nm and able to encapsulate hydrophobic (flurbiprofen), hydrophilic (paeoniflorin), and 
amphiphilic (berberin) drugs were efficiently prepared by this method 228. Another interesting method for preparing nanovesicles 
was reported by Yu et al. and consists of the production of nanofibers composed by phospholipids and a hydrophilic polymer 
(filament-forming matrix) by electrospinning first, serving as liposomes precursors 231. 
 
Figure 10. Schematic representation of the freeze-drying of emulsions 
method. Reprinted from Ref. 228, Chem. Phys. Lipids, 2011, 164, 151–
157. T. Wang, N. Wang, T. Wang, W. Sun and T. Li., “Preparation of 
submicron liposomes exhibiting efficient entrapment of drugs by 
freeze-drying water-in-oil emulsions”, Copyright 2016, with permission 
from Elsevier. 
 
When in contact to an aqueous solution the hydrophilic 
polymer disperses into the solution, releasing the phospholipids that self-assemble into vesicles. Through this technique was 
possible to produce nanovesicles of PC smaller than 200 nm from PC: polyvinylpyrrolidone (PVP) nanofibers. In this case, the size 
of the liposomes can be controlled by changing the ratio of PC:PVP used to produce nanofibers. This method presents some 
advantages over conventional methods since is free of heating, cooling, agitation, or postformation steps 231, but it also has some 
drawbacks mainly related to its scalability. 
Biomedical applications of nanovesicles 
Nanovesicles for delivery of pharmaceuticals 
Many therapeutics have been benefiting with the development of Nanomedicine, and among them, anticancer drugs are the 
most studied ones and presenting the highest number of approved or under clinical evaluation nano-based drug products 232. 
The important progresses observed in the cancer treatment have resulted, in the last two decades, in an improvement of the 
clinical outcomes and a decrease of the mortality rates 233. Different nanovesicles have been proposed as vehicles of anticancer 
agents including paclitaxel 234,68, doxorubicin 235,236, vinorelbine 237, cisplatin 238, 5-fluorouracil 112, lapatinib 239, among others, 
with some formulations marketed and used in clinical practice (Table 4) or even enrolling clinical evaluation (Table 5). As 
previously mentioned in this Review, among the different nano-based products available, liposomes have been the systems 
more studied, being the first nanomedicines reaching the market (Doxil/Caelyx®). As referred, Doxil/Caelyx® was the first 
nanomedicine-based system reaching the market in 1995, and its success boosted the development of new nanotechnology-
based DDS. This stealth liposomes (around 100 nm) composed of MPEG-DSPE, HSPC and Chol encapsulating doxorubicin were 
able to alter the biodistribution of the drug and increase its half-life, increasing therefore its therapeutic efficacy (passively 
targeting the tumors) and reducing its well-known side effects, namely cardiotoxicity and neutropenia 240,241. One of the most 
interesting characteristics of Doxil/Caelyx® is related to its smart drug loading mechanism based in the use of transmembrane 
ammonium sulfate gradients to actively load amphipathic weak bases like doxorubicin after liposomes production. This method 
not only allows the entrapment of high amounts of the drug in the small aqueous core of liposomes without requiring 
preparation of their in acidic pH nor alkalization of the extra-liposomal aqueous phase, but also presents a strong loading 
stability of the drug both in storage and blood circulation 241,242. 
Together with liposomes, other vesicular systems, especially non-liposomal L-NVs, have been developed and proposed as 
promising and alternative DDS in the last years. Table 4 and 5 report some examples of nanovesicles-based drug products 
already on the market or under clinical evaluation. Liposomes and niosomes have shown to improve the oral bioavailability of 
paclitaxel, a Biopharmaceutical Classification System (BCS) class IV drug whose oral delivery is highly impaired by its 
physicochemical characteristics 243,244. Liposomes coated with poly(acrylic acid) and poly(allylamine hydrochloride) were also 
able to improve the oral bioavailability of doxorubicin, and present an in vivo antitumor activity after a multiple oral dose 
regimen comparable to a single intra venous administration of the commercial formulation Lipo-Dox® 245. In another study, the 
surface modification of liposomes encapsulating doxorubicin with anti-HER2/neu peptide (AHNP) improved the in vivo 
therapeutic index and anticancer activity of the drug against breast cancer when compared with non-targeted liposomes such as 
Caelyx® (Figure 11) 236. The encapsulation of mitoxantrone into ethosomes improved its anticancer activity against melanoma 
tumors by a reduction in the tumor size and an induction of an in vivo anticancer immune response 246. In another study, 5-
fluorouracil intended for dermal application was encapsulated into liposomes, transfersomes and niosomes. All the vesicular 
systems promoted an improvement of the biopharmaceutical characteristics of the drug, being transfersomes the vehicle that 
presented the best anticancer activity due to higher penetration capacity 247. The topical administration of anticancer drugs 
could be an effective and safer way to treat skin cancer over conventional therapies since they reduce the systemic side effects 
and an increase of the therapeutic index of drugs. 
 
Figure 11. Preparation (a) and efficacy assessment (b) of AHNP modified 
liposomes encapsulating doxorubicin. In the in vivo studies the mean 
relative change in tumor volume in bearing mice treated with a dose of 
15 mg/kg DOX formulations or dextrose 5% as i.v. injection on day 13 
after tumor inoculation was assessed over time. Reprinted from Ref. 
236, Eur J Pharm Sci, 2016, 86, 125–135. M. Zahmatkeshan, F. Gheybi, S. 
Mahdi Rezayat, M. Reza Jaafari “Improved drug delivery and 
therapeutic efficacy of PEgylated liposomal doxorubicin by targeting 
antiHER2 peptide in murine breast tumor model”, Copyright 2016, with 
permission from Elsevier. 
 
Resistant infectious diseases, especially the nosocomial respiratory infections, impose a challenge to the current available clinical 
therapeutic regimens. In this context, DDS based on nanotechnology, including nanovesicles, arise as promising alternatives to 
improve the therapeutic index and clinical relevance of anti-infectious drugs. Many research groups have been developing 
liposomes for encapsulation of anti-infectious drugs like tobramycin 248,249, polymyxin B 250, amphotericin B 251, or ciprofloxacin 
252–256. For example, administration of ciprofloxacin-loaded liposomes resulted in at least 86% survival of animals suffering from 
lethal tularemia 14 days post-administration 253, while liposomal tobramycin was therapeutically more effective than the 
conventional formulation (Tobi®, PathoGenesis Canada) against Pseudomonas aeruginosa and Burkholderia cepacia in a multiple 
dose treatment conducted in infected rats 248,249. Some of the most severe infectious diseases like Tuberculosis, HIV or Legionella 
are induced by intracellular pathogens that infect internally the cells, evading from the mononuclear phagocyte system and 
turning them as reservoirs 257.  
The intracellular localization of the pathogens becomes an obstacle to an effective and prompt treatment due to the difficulties 
of drugs present in conventional formulations to reach the therapeutic targets 257. For presenting a higher cellular uptake, nano-
DDS have been proposed as improved systems to delivery drugs at effective doses to the cytosol of cells. For example, the 
administration of streptomycin 258,259, kanamycin 260, amikacin 261,262, and gentamicin 263 encapsulated into liposomes increased 
their in vivo efficacy by reducing the viable bacteria counts of pathogens such as Mycobacterium tuberculosis and Klebsiella 
pneumoniae. Regarding macrophages targeting, the encapsulation of rifampicin into PC:Chol:dicetylphosphate liposomes 
imposed a significant reduction of the Mycobacterium smegmatis viability inside macrophages compared to the free drug. The 
modification of the liposome surfaces with antigens such as maleylated bovine serum albumin (MBSA) and O-steroyl 
amylopectin (O-SAP) to actively targeting macrophages further improve the therapeutic efficacy of the systems 264. In other 
studies, mannosylated liposomes improved the uptake of ciprofloxacin by alveolar macrophages 254, while O-palmitoyl mannan 
(OPM) and O-polmitoyl pullulan (OPP) were used as ligands to target amphotericin B-loaded PC:Chol liposomes to alveolar 
macrophages 251. 
Referring to the non-liposomal L-NVs, transfersomes due to their ultraflexibility and ethosomes due to their content in ethanol 
offer the better features for improved skin drug delivery 117,265–267. Transfersomes have been proposed as delivery systems of 
drugs with different applications, such as meloxicam 268 and diclofenac 269 for the treatment of rheumatoid arthritis, raloxifene 
for the treatment of breast cancer 270, sertraline for the treatment of depression 42, amphotericin B for the treatment of 
Leishmaniasis 271, ketoconazole for the treatment of fungal infections 272 or felodipine for the treatment of hypertension 273. For 
example, transfersomes composed by Span 80, soya lecithin, and Carbopol 940 were proposed for transdermal delivery of 
sertraline as alternative to its oral administration in order to avoid the hepatic first-pass metabolism and reduce the required 
doses. The transfersomes improved both ex vivo and in vivo permeation and therapeutic activity of sertraline compared to the 
drug in solution or  gel 42. In another study, transfersomes have also shown to improve the skin permeation and the efficacy of 
amphotericin B against L. donovani when compared to a conventional liposomal formulation, being a promising alternative to 
the treatment of visceral Leishmaniasis 271. Regarding ethosomes, Ahmed, et al. (2016) developed ethosomes composed by PC, 
Chol, ethanol and propylene glycol, encapsulating the anti-diabetic drug glimepiride, intended for transdermal systemic delivery 
when incorporated into a transdermal patch 274. As previously mentioned, ethosomes promoted higher skin permeation and also 
show a superior bioavailabity of the drug in human volunteers, compared to the free drug in the patch, becoming a promising 
alternative to the oral delivery of glimepiride 274. Other studies propose ethosomes as dermal and nasal delivery systems of drugs 
like aceclofenac 69, zolmitriptan 275, piroxicam 276, lidocaine 277, celecoxib 278 or methoxsalen 92. Niosomes have been proposed as 
vehicles for delivery of a variety of drugs via different administration routes, arising as promising carriers for ocular delivery 77,279. 
Tracrolimus-loaded niosomes have shown to be biocompatible with the cornea, delaying the occurrence of corneal allograft 
rejection in transplanted animals to a higher extent than free drug and the typical CsA treatment 280. Other drugs like fluconazole 
281, naltrexone 282, gentamicin 283, or prednisolone 284 have also been encapsulated into niosomes presenting interesting results. 
 
Table 4. Examples of vesicular formulations with marketed authorization. CM – Conventional method; NCM – Non-conventional method. 
Preparation 
Method Type of vesicle Drug Disease Trade name Manufacturer 
CM Liposomes Amphotericin B Severe fungal infections AmBisome Gilead Sciences, Inc. 
CM Liposomes Daunorubicin Advanced HIV-related Kaposi's sarcoma DaunoXome Galen Limited 
CM Liposomes Doxorubicin Metastatic breast cancer Myocet 
Teva Pharmaceutical 
Industries Ltd. 
 
CM Liposomes Doxorubicin 
Ovarian cancer   and 
HIV-related Kaposi's 
sarcoma 
Doxil/Caelyx Janssen Products 
CM Sphingosomes Vincristine Acute lymphoblastic leukemia Marqibo 
Spectrum Pharmaceuticals, 
Inc. 
CM Liposomes Mifamurtide Osteosarcoma Mepact Takeda Pharmaceutical Company Limited 
CM Liposomes Doxorubicin 
Kaposi's sarcoma, 
breast and ovarian 
cancer 
Lipo-Dox Taiwan Liposome 
CM Liposomes Verteporfin 
Age-related macular 
degeneration, ocular 
histoplasmosis 
Visudyne Novartis AG 
CM Liposomes Irinotecan 
Metastatic 
adenocarcinoma of the 
pancreas 
Onivyde Merrimack Pharmaceuticals, Inc. 
CM Liposomes Paclitaxel Advancer solid tumours Lipusu Luye Pharma Group 
CM 
Virosomes 
(vaccine) 
Inactivated 
hepatitis A 
antigen 
Hepatitis A Epaxal Crucell 
CM Virosomes (vaccine) 
Inactive 
hemagglutinin 
of influenza 
virus strains A 
and B 
Influenza Inflexal V Crucell 
NCM Liposomes Cisplatin Pancreatic cancer Lipoplatin Regulon Inc 
Nanovesicles for delivery of biopharmaceuticals 
L-NVs have shown to be good carrier candidates for the delivery of biopharmaceuticals as well. As for pharmaceuticals, 
liposomes are the most studied and proposed lipid-based nanovesicles and have shown up to now the most promising results 
both in vitro and in vivo. However, as referred before, they also present some limitations, such as a low therapeutic efficacy, a 
poor long-term stability and a low transfection efficiency in the case of nucleic acid delivery 25,31,66. Fewer examples of liposomal 
formulations for delivering biopharmaceuticals are nowadays under clinical evaluation, and these are still in the early stage. This 
low number of products enrolling clinical trials is related with the poor stability of biopharmaceuticals during its formulation, and 
challenges observed in the pilot to industrial scale-up of the methods of preparation used for these novel products. Liposomal 
formulations in clinical trials display a large variety of loaded biopharmaceutical drugs, such as insulin, Grb2 antisense 
oligonucleotide, siRNA against PKN3, p53 plasmid DNA, RSV SHe Antigen, among others (Table 4). Liposomes have shown to 
improve pharmacological properties of peptides and proteins, and several enzymes have been proposed for liposomal delivery 
such as glucose oxidase, glucose-6-phosphate dehydrogenase, hexokinase, β-galactosidase, β-glucuronidase, glucocerebrosidase, 
α-mannosidase or amiloglucosidase 285. For example, liposomes have been used to improve both the bioavailability and 
absorption of proteins in the harsh environment of the intestinal tract (strong acidic medium and presence of enzymes) 286. In 
another study, after administration of liposomes containing β-fructofuranosidase in rats, it was observed that within an hour, 
50% of the administered enzyme remain in the circulation, and the activity of the enzyme was preserved at least after 2 days in 
the liver 287. After oral administration of insulin and sodium taurocholate loaded on a liposome system it was observed a 
markedly reduction on the blood glucose levels both in vitro and in vivo 288. However, another study in patients using insulin 
loaded into liposomes for the treatment of Type-2 diabetes mellitus, showed that insulin did not delay or prevent type 1 
diabetes 289. Moreover, several absorption enhancers, such as fatty acids, surfactants and bile salts, have been used in animal 
models for the oral delivery of biomacromolecules 290. Furthermore, it has been demonstrated the ability of liposomes to enter 
into the cytoplasm and lysosomes of live cells, which open new opportunities for the treatment of inherited diseases caused by 
the abnormal function of the enzymes. For example, liposome containing β-galaclosidase were able to degrade glycopeptides 
(GM1-ganglioside) accumulated in lysosomes of feline fibroblasts, which have deficient β-galactosidase activity 291. Many studies 
also have been performed using transfersomes for protein and peptide delivery. For example, buccal delivery of insulin was 
achieved when transfersomes were used, showing an intercellular transdermal transfer rates of the order of 50%; however 
recent studies have been unable to reproduce these initial results 292. Morrow and co-workers found a reduction in the glucose 
levels of both in mice and humans, after transcutaneous administration of insulin loaded into transfersomes 293. Transfersomes 
have been shown promising results for delivery of calcitonin, α- and γ-interferon, Cu-Zn superoxide dismutase, and serum 
albumin across the skin 294. Moreover, transfersomes have been able to deliver genetic material into the cells 295. For example, 
cationic transfersomes have been used as carriers for topical administration of plasmid DNA encoding hepatitis B surface antigen 
(HBsAg). After topical administration of these HBsAg-loaded cationic transfersomes it was observed a significantly higher anti-
HBsAg antibody titer and cytokines levels compared with naked DNA 71.  
Up to now, there are only two clinically approved L-NVs for biopharmaceutical delivery, Epaxal® and Inflexal V®, which are 
liposome-based vaccine products, classified as virosomes. Epaxal® is a hepatitis A virus vaccine which is based on an inactivated 
hepatitis A antigen anchored into the virosomes. Inflexal V® is an influenza virus vaccine which is based on inactive hemagglutinin 
of influenza virus strains A and B anchored into virosomes. Both vaccines are approved for intramuscular administration, are 
well-tolerated, safe, and show effective and durable immunization against the viruses by strong stimulation of the immune 
system 240.
 
Table 5. Examples of vesicles for delivery of pharmaceuticals and biopharmaceuticals under clinical evaluation. CP – Clinical trial phase; CM – 
Conventional method; NCM – Non-conventional method. 
Preparation 
Method 
Type of 
vesicle Drug Disease Name CP Ref. 
CM Liposomes 24-mer oligonucleotide targeting BCL-2 
Non-Hodgkin's Lymphoma and 
Richter's Transformation PNT2258 2 
296,297 
CM Liposomes Amikacin Cystic Fibrosis, Bronchiectasis Arikace 3 298 
CM Liposomes Belotecan Advanced Malignancies S-CKD602 1 299 
CM Liposomes Cisplatin Advanced or refractory solid tumours LiPlaCis 1 
300 
CM Liposomes Cisplatin Ovarian Cancer SPI-077 2 301 
CM Liposomes Cisplatin analog Advanced solid tumours Aroplatin 2 302 
CM Liposomes C-RAF Antisense Oligodeoxynucleotide 2 Advanced Solid Tumors LErafAON 1 
303 
CM Liposomes Curcumin Cancer Lipocurc 2 304 
CM Liposomes Cytarabine:daunorubicin Myelodysplastic syndrome and acute myeloid leukemia Vyxeos 3 
305,306 
CM Liposomes Docetaxel Advanced or Metastatic Pancreatic Cancer LE-DT 2 
307 
CM Liposomes Doxorubicin Liver, breast and pancreatic cancer ThermoDox 3 
308,309 
CM Liposomes Doxorubicin Brain metastases of breast cancer 2B3-101 2 
310 
CM Liposomes Doxorubicin Advanced/Metastatic Breast Cancer Patients MM-302 3 
311 
CM Liposomes (vaccine) 
HLA-A2-restricted peptides, T 
Helper Peptide, polynucleotide 
adjuvant 
Advanced Stage Ovarian, Breast 
and Prostate Cancer DPX-0907 1 
312 
CM Liposomes Insulin Type-2 diabetes mellitus HDV-I 3 313 
CM Liposomes Irinotecan:Floxuridine Advanced Colorectal Cancer CPX-1 2 314 
CM Liposomes Lurtotecan Solid tumours OSI-211 2 315,316 
CM Liposomes MicroRNA RX34 Solid tumors and hematologic malignancies MRX34 1 
317 
CM Liposomes Mitomycin-C Lipid-based Prodrug Solid Tumors Promitil 1 318 
CM Liposomes Mitoxantrone Solid tumours LEM-ETU 1 319 
CM Liposomes p53 Glioblastoma, Metastatic Pancreatic Cancer SGT-53 2 
320,321 
CM Liposomes Paclitaxel Advanced breast cancer LEP-ETU 2 322 
CM Liposomes Paclitaxel Breast, pancreas and liver tumours EndoTag-1 2 
323,324 
CM Liposomes Prednisolone Hemodialysis fistula maturation and Rheumatoid arthritis Nanocort 3 
325,326 
CM Liposomes RB94 plasmid DNA Solid tumours SGT-94 1 327 
CM Liposomes (vaccine) RSV SHe Antigen 
Respiratory Syncytial 
Virus infection DPX-RSV 1 
328 
CM Liposomes siRNA against PKN3 Advanced Solid tumours and pancreatic cancer Atu027 2 
329,330 
CM Liposomes SN38 Colorectal Cancer LE-SN38 2 331 
CM Liposomes (vaccine) Survivin 
Advanced Stage Ovarian, 
Fallopian or Peritoneal Cancer 
DPX-
Survivac 2 
332 
CM Liposomes (vaccine) Tecemotide 
Non-Small Cell Lung Cancer, 
solid tumours Stimuvax 3 
333–
335 
CM Liposomes Thymidylate synthase inhibitor Advanced Solid Tumors OSI-7904L 2 336,337 
CM Sphingosomes Topotecan Advanced solid tumours Brakiva 1 338,339 
CM Sphingosomes Vinorelbine 
Advanced solid tumors, non-
Hodgkin’s and Hodgkin’s 
lymphoma 
Alocrest 1 340 
CM Transfersomes Papaverine hydrochloride  Erectile dysfunction ------- 1 341 
NCM Liposomes 9-Nitro-20-(S)-Camptothecin Non-small-cell lung cancer and metastatic endometrial cancer L9NC 2 
342,343 
NCM Liposomes Docetaxel Solid tumours ATI-1123 1 344 
NCM Liposomes 
Growth Factor Receptor Bound 
Protein-2 Antisense 
Oligonucleotide 
Leukemia BP1001 1 345 
Conclusions and Future Perspectives 
The second generation of L-NVs, by complementing liposomes, showing their advantages and overcoming most of their 
drawbacks, is emerging day-by-day among the large variety of nanocarriers available and it has all the potential to represent a 
paradigm shift in Nanomedicine. Up to now there are only few non-liposomal L-NVs commercialized or under clinical studies, but 
their ancestors, liposomes, have already shown the full potential of L-NVs as nanocarriers both for synthetic drugs and 
biopharmaceuticals delivery, stepping from the lab-bench to the clinical practice. Among the non-liposomal L-NVs developed, 
sphingosomes and virosomes have shown to be the most successful ones by reaching clinical use. Nevertheless, other types of 
non-liposomal L-NVs such as quatsomes, niosomes, transfersomes and ethosomes have been showing promising in vitro and in 
vivo results in a variety of applications. Thus, it would be expected that in the near future, the pipeline of Pharmaceutical 
Industries will be fulfilled by non-liposomal L-NVs drug products to treat many diseases, not only limited to oncology and 
vaccines which will definitively impose their presence in the market and clinical use. Conventional methods are nowadays 
predominantly exploited to prepare the commercially available lipid-based drug formulations, yielding final products many times 
not fully homogeneous, and that can be contaminated to some extent with residual organic solvents. Furthermore, their scale-up 
from lab scale to the industrial scenario of these multistep processes, in a controlled way, granting high-quality products, is not 
easy at all, arising as major drawback that limit the translation of these systems from the bench to the bedside. In this frame, CF-
based technologies are everyday stepping forward as promising alternatives: their affordable cost, simplicity, high throughputs 
of L-NVs with controlled physicochemical properties and almost no trace of residual solvents, as well as their great flexibility and 
easy scalability make them ideal methods for pharmaceutical companies. Taking all of these into consideration, we strongly 
believe that CF technologies have a bright future in playing an important role in the development and production of improved L-
NVs drug formulations, and that they will support these outstanding nanocarriers during their rocky way from the preclinical 
stages, through its translation to clinic phases, and then finally to the market.  
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